ATF4 and bronchiolitis obliterans syndrome: Our findings suggest the YAP/TAZ‐mTORC1‐ATF4 axis as a potential therapeutic target for human fibrotic lung diseases such as BO by modulating the differentiation program of secretory or DATP cells in PF lungs.